199 related articles for article (PubMed ID: 29633884)
1. Gelatinolytic activity of autocrine matrix metalloproteinase-9 leads to endothelial de-arrangement in Moyamoya disease.
Blecharz-Lang KG; Prinz V; Burek M; Frey D; Schenkel T; Krug SM; Fromm M; Vajkoczy P
J Cereb Blood Flow Metab; 2018 Nov; 38(11):1940-1953. PubMed ID: 29633884
[TBL] [Abstract][Full Text] [Related]
2. Autocrine release of angiopoietin-2 mediates cerebrovascular disintegration in Moyamoya disease.
Blecharz KG; Frey D; Schenkel T; Prinz V; Bedini G; Krug SM; Czabanka M; Wagner J; Fromm M; Bersano A; Vajkoczy P
J Cereb Blood Flow Metab; 2017 Apr; 37(4):1527-1539. PubMed ID: 27381827
[TBL] [Abstract][Full Text] [Related]
3. Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease.
Rafat N; Beck GCh; Peña-Tapia PG; Schmiedek P; Vajkoczy P
Stroke; 2009 Feb; 40(2):432-8. PubMed ID: 19095988
[TBL] [Abstract][Full Text] [Related]
4. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease.
Kang HS; Kim JH; Phi JH; Kim YY; Kim JE; Wang KC; Cho BK; Kim SK
J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):673-8. PubMed ID: 19965844
[TBL] [Abstract][Full Text] [Related]
5. Assessment of plasma soluble Tie-2 level to distinguish moyamoya disease from atherosclerotic cerebrovascular disease and predict postoperative neovascularization.
Chen T; Wei W; Zhang J; Yu J; Xu S; Wu D; Li X; Chen J
J Neurosurg; 2023 Dec; 139(6):1705-1714. PubMed ID: 37347656
[TBL] [Abstract][Full Text] [Related]
6. In vivo demonstration of blood-brain barrier impairment in Moyamoya disease.
Narducci A; Yasuyuki K; Onken J; Blecharz K; Vajkoczy P
Acta Neurochir (Wien); 2019 Feb; 161(2):371-378. PubMed ID: 30675657
[TBL] [Abstract][Full Text] [Related]
7. Increased vascular MMP-9 in mice lacking RNF213: moyamoya disease susceptibility gene.
Sonobe S; Fujimura M; Niizuma K; Fujimura T; Furudate S; Nishijima Y; Kure S; Tominaga T
Neuroreport; 2014 Dec; 25(18):1442-6. PubMed ID: 25383461
[TBL] [Abstract][Full Text] [Related]
8. Proteomic Profiling of Exosomes From Hemorrhagic Moyamoya Disease and Dysfunction of Mitochondria in Endothelial Cells.
Wang X; Han C; Jia Y; Wang J; Ge W; Duan L
Stroke; 2021 Oct; 52(10):3351-3361. PubMed ID: 34334053
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of serum Matrix Metalloproteinase-9 in patients with moyamoya disease.
Fujimura M; Watanabe M; Narisawa A; Shimizu H; Tominaga T
Surg Neurol; 2009 Nov; 72(5):476-80; discussion 480. PubMed ID: 19147196
[TBL] [Abstract][Full Text] [Related]
10. Differential Expression of Vascular Endothelial Growth Factor-A
Jiang H; Toscano JF; Schiraldi M; Song SS; Schlick KH; Dumitrascu OM; Liou R; Lyden PD; Pan J; Zhan R; Saver JL; Gonzalez NR
J Stroke Cerebrovasc Dis; 2019 Feb; 28(2):360-368. PubMed ID: 30392834
[TBL] [Abstract][Full Text] [Related]
11. Vasculogenic and Angiogenic Pathways in Moyamoya Disease.
Bedini G; Blecharz KG; Nava S; Vajkoczy P; Alessandri G; Ranieri M; Acerbi F; Ferroli P; Riva D; Esposito S; Pantaleoni C; Nardocci N; Zibordi F; Ciceri E; Parati EA; Bersano A
Curr Med Chem; 2016; 23(4):315-45. PubMed ID: 26861126
[TBL] [Abstract][Full Text] [Related]
12. Circulating endothelial progenitor cells as a pathogenetic marker of moyamoya disease.
Jung KH; Chu K; Lee ST; Park HK; Kim DH; Kim JH; Bahn JJ; Song EC; Kim M; Lee SK; Roh JK
J Cereb Blood Flow Metab; 2008 Nov; 28(11):1795-803. PubMed ID: 18612318
[TBL] [Abstract][Full Text] [Related]
13. Circulating miRNome profiling in Moyamoya disease-discordant monozygotic twins and endothelial microRNA expression analysis using iPS cell line.
Uchino H; Ito M; Kazumata K; Hama Y; Hamauchi S; Terasaka S; Sasaki H; Houkin K
BMC Med Genomics; 2018 Aug; 11(1):72. PubMed ID: 30157848
[TBL] [Abstract][Full Text] [Related]
14. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis.
Adya R; Tan BK; Punn A; Chen J; Randeva HS
Cardiovasc Res; 2008 May; 78(2):356-65. PubMed ID: 18093986
[TBL] [Abstract][Full Text] [Related]
15. Significance of cyclooxygenase-2 elevation in middle cerebral artery for patients with hemorrhagic moyamoya disease.
Zhang JJ; Xiong ZW; Wang S; Sun SJ; Wang H; Wu XL; Wang L; Zhang HQ; You C; Wang Y; Chen JC
J Huazhong Univ Sci Technolog Med Sci; 2016 Apr; 36(2):181-185. PubMed ID: 27072959
[TBL] [Abstract][Full Text] [Related]
16. MMP-9 as a Biomarker for Predicting Hemorrhagic Strokes in Moyamoya Disease.
Lu J; Wang J; Lin Z; Shi G; Wang R; Zhao Y; Zhao Y; Zhao J
Front Neurol; 2021; 12():721118. PubMed ID: 34531816
[No Abstract] [Full Text] [Related]
17. GM-CSF Promotes the Development of Dysfunctional Vascular Networks in Moyamoya Disease.
Li H; Cao X; Gu X; Dong M; Huang L; Mao C; Xia S; Yang H; Bao X; Yang Y; Xu Y
Neurosci Bull; 2024 Apr; 40(4):451-465. PubMed ID: 38113014
[TBL] [Abstract][Full Text] [Related]
18. Deregulation of Retinaldehyde Dehydrogenase 2 Leads to Defective Angiogenic Function of Endothelial Colony-Forming Cells in Pediatric Moyamoya Disease.
Lee JY; Moon YJ; Lee HO; Park AK; Choi SA; Wang KC; Han JW; Joung JG; Kang HS; Kim JE; Phi JH; Park WY; Kim SK
Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1670-7. PubMed ID: 26023078
[TBL] [Abstract][Full Text] [Related]
19. The prognostic values of plasma desmosines, crosslinking molecules of elastic fibers, in the disease progression of Moyamoya disease.
Tashiro R; Anzawa R; Inoue T; Mikagi A; Ozaki D; Tominaga K; Inoue T; Ishida T; Fujimura M; Usuki T; Endo H; Niizuma K; Tominaga T
Bioorg Med Chem; 2024 Feb; 100():117602. PubMed ID: 38324946
[TBL] [Abstract][Full Text] [Related]
20. Impaired functional recovery of endothelial colony-forming cells from moyamoya disease in a chronic cerebral hypoperfusion rat model.
Choi SA; Chong S; Kwak PA; Moon YJ; Jangra A; Phi JH; Lee JY; Park SH; Kim SK
J Neurosurg Pediatr; 2018 Nov; 23(2):204-213. PubMed ID: 30668528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
